Infliximab treatment for symptomatic Crohn’s disease strictures
- 22 December 2008
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (3), 279-285
- https://doi.org/10.1111/j.1365-2036.2008.03887.x
Abstract
Some reports have suggested that infliximab may induce obstructive symptoms and, although there is no firm evidence, it is usually contra-indicated in-patients with Crohn's disease (CD) and strictures.To evaluate the effect of infliximab on symptomatic strictures of the small intestine in CD and to identify predictive factors of clinical response.This retrospective study included symptomatic patients treated with infliximab after conventional treatment had failed. The short-term (week 8) and long-term results were classified according to predefined criteria as complete, partial response, or failure.Before infliximab, 18 patients had complete obstruction or intermittent chronic abdominal pain. Fourteen patients were treated by corticosteroids and 13 received immunosuppressive drugs. At week 8, complete, partial response and failure were observed in 10, 7 and 1 patients, respectively. Fourteen patients continued maintenance infliximab treatment after week 8. During the most recent evaluation (median follow-up: 18 months), 8 patients were on maintenance infliximab treatment; only eight were still on prednisone; there were five complete responses, 10 partial responses and three failures. Initiating prednisone or increasing its dosage was the only factor associated with a short-term complete response.Infliximab may be effective in patients with symptomatic strictures from CD, and should be tested before considering surgery.Keywords
This publication has 26 references indexed in Scilit:
- Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Gut, 2007
- Review article: altering the natural history of Crohn's disease – evidence for and against current therapiesAlimentary Pharmacology & Therapeutics, 2006
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006
- New Diagnostic Avenues in Inflammatory Bowel DiseasesDigestive Diseases, 2003
- Endoscopic healing of Crohn's Ileo-colitis with azathioprineGastroenterology, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Influence of treatment on morphological features of mucosal inflammationGut, 2002
- Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complicationGastroenterology, 2000
- Oral budesonide for prevention of postsurgical recurrence in Crohn's diseaseGastroenterology, 1999
- Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms.Gut, 1992